CLAIMS

What is claimed is:

1. An isolated target binding member that binds IL-25, wherein the target bindingcomprises an antibody light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence SASQGISNYLN (SEQ ID NO:6) and a CDR2 having the amino acid sequence YTSSLHS (SEQ ID NO:7) and a CDR3 having the amino acid sequence QQYLAFPYTF (SEQ ID NO:8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence GYTMN (SEQ ID NO:10), a CDR2 having the amino acid sequence LINPYNGGTSYNQNFKG (SEQ ID NO:11) and a CDR3 having the amino acid sequence EDYDGYLYFAMDY (SEQ ID NO:12).

2. The target binding member of claim 1, wherein the target binding member binds amino acid residues 56-63 of SEQ ID NO:17 and amino acid residues 66-74 of SEQ ID NO:17.

3. The target binding member of claim, wherein the target binding member binds one or more amino acid sequences selected from the group consisting of amino acid residues 46-63 of SEQ ID NO:17 or amino acid residues 66-84 of SEQ ID NO:17.

4. The isolated target binding member of claim 1, wherein the VL domain comprises amino acid residues 1-107 of SEQ ID NO:5.

5. The isolated target binding member of claim 1, wherein the VH domain comprises amino acid residues 1-122 of SEQ ID NO:9.

6. The isolated target binding member of claim 1, wherein the target binding member comprises an antibody constant region.

7. The isolated target binding member of claim 6, wherein the antibody constant region is an IgG1 constant region or an IgG4 constant region.

8. The isolated target binding member of claim 7, wherein the target binding member comprises a whole antibody.

9. The isolated target binding member of claim 1, wherein the target binding member comprises an antibody fragment selected from the group consisting of a Fab antibody fragment, a $F(ab')_2$ antibody fragment, and an scFv antibody fragment.

10. A composition comprising the isolated target binding member of claim 1and a pharmaceutically acceptable carrier.

11. The composition of claim 10, wherein the composition comprises a lyophilized powder.

12. The isolated target binding member of claim 1for use in the treatment or prevention of asthma.

13. The isolated target binding member of claim 1for use in the treatment or prevention of an inflammatory bowel disease.

14. The isolated target binding member of claim 13, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

15. The isolated target binding member of claim 1, wherein the target binding member has a binding affinity for human IL-25 that is less than or equal to about 50 pM.

16. The isolated target binding member of claim 1wherein the target binding member comprises:

a) an antibody VL domain comprising an amino acid sequence having from 1 to about5 amino acid substitutions relative to the amino acid sequence of amino acid residues 1-107 of SEQ ID NO:5; and

b) an antibody VH domain comprising an amino acid sequence having from 1 to about 5 amino acid substitutions relative to the amino acid sequence of amino acid residues 1-122 of SEQ ID NO:9;wherein the VL domain comprises a CDR3 having the amino acid sequence QQYLAFPYTF (SEQ ID NO: 8).

17. The isolated target binding member of claim 1, wherein the target binding member comprises a humanized antibody.

CLAIMS

What is claimed is:

1. An isolated target binding member that binds IL-25, wherein the target binding comprises an antibody light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence SASQGISNYLN (SEQ ID NO:6) and a CDR2 having the amino acid sequence YTSSLHS (SEQ ID NO:7) and a CDR3 having the amino acid sequence QQYLAFPYTF (SEQ ID NO:8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence GYTMN (SEQ ID NO:10), a CDR2 having the amino acid sequence LINPYNGGTSYNQNFKG (SEQ ID NO:11) and a CDR3 having the amino acid sequence EDYDGYLYFAMDY (SEQ ID NO:12).

2. The target binding member of claim 1, wherein the target binding member binds amino acid residues 56-63 of SEQ ID NO:17 and amino acid residues 66-74 of SEQ ID NO:17.

3. The target binding member of claim 1, wherein the target binding member binds one or more amino acid sequences selected from the group consisting of amino acid residues 46-63 of SEQ ID NO:17 or amino acid residues 66-84 of SEQ ID NO:17.

4. The isolated target binding member of claim 1, wherein the VL domain comprises amino acid residues 1-107 of SEQ ID NO:5.

5. The isolated target binding member of claim 1, wherein the VH domain comprises amino acid residues 1-122 of SEQ ID NO:9.

6. The isolated target binding member of claim 1, wherein the target binding member comprises an antibody constant region.

7. The isolated target binding member of claim 6, wherein the antibody constant region is an IgG1 constant region or an IgG4 constant region.

8. The isolated target binding member of claim 7, wherein the target binding member comprises a whole antibody.

9. The isolated target binding member of claim 1, wherein the target binding member comprises an antibody fragment selected from the group consisting of a Fab antibody fragment, a $F(ab')_2$ antibody fragment, and an scFv antibody fragment.

10. A composition comprising the isolated target binding member of claim 1and a pharmaceutically acceptable carrier.

11. The composition of claim 10, wherein the composition comprises a lyophilized powder.

12. The isolated target binding member of claim 1 for use in the treatment or prevention of asthma.

13. The isolated target binding member of claim 1 for use in the treatment or prevention of an inflammatory bowel disease.

14. The isolated target binding member of claim 13, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

15. The isolated target binding member of claim 1, wherein the target binding member has a binding affinity for human IL-25 that is less than or equal to about 50 pM.

16. The isolated target binding member of claim 1wherein the target binding member comprises:

a) an antibody VL domain comprising an amino acid sequence having from 1 to about5 amino acid substitutions relative to the amino acid sequence of amino acid residues 1-107 of SEQ ID NO:5; and

b) an antibody VH domain comprising an amino acid sequence having from 1 to about 5 amino acid substitutions relative to the amino acid sequence of amino acid residues 1-122 of SEQ ID NO:9;wherein the VL domain comprises a CDR3 having the amino acid sequence QQYLAFPYTF (SEQ ID NO: 8).

17. The isolated target binding member of claim 1, wherein the target binding member comprises a humanized antibody.